Aegis Capital Broadens Coverage on Signal Genetics (SGNL); Affirms at 'Buy'
Tweet Send to a Friend
Aegis Capital affirmed Signal Genetics, Inc. (Nasdaq: SGNL) with a Buy rating and $3 price target amid a broadening of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
